Evolent Health, Inc (NYSE:EVH) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Evolent Health, Inc (NYSE:EVH) have earned an average recommendation of “Moderate Buy” from the sixteen ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $11.0357.

Several analysts have recently commented on the company. BTIG Research lowered their price objective on Evolent Health from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolent Health in a report on Monday, December 29th. Citizens Jmp dropped their price objective on Evolent Health from $13.00 to $11.00 and set a “market outperform” rating on the stock in a research note on Monday, November 10th. Oppenheimer cut their price objective on shares of Evolent Health from $18.00 to $12.00 and set an “outperform” rating on the stock in a report on Wednesday, November 12th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Evolent Health from $13.00 to $7.00 and set an “overweight” rating for the company in a report on Monday, November 17th.

Insider Transactions at Evolent Health

In other news, Director Brendan B. Springstubb acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, November 18th. The stock was purchased at an average price of $3.82 per share, for a total transaction of $38,200.00. Following the purchase, the director owned 58,821 shares in the company, valued at approximately $224,696.22. This represents a 20.48% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Evolent Health

Institutional investors have recently modified their holdings of the business. Brighton Jones LLC purchased a new position in Evolent Health in the fourth quarter valued at approximately $3,927,000. Geode Capital Management LLC raised its stake in shares of Evolent Health by 3.1% in the second quarter. Geode Capital Management LLC now owns 2,667,642 shares of the technology company’s stock valued at $30,041,000 after buying an additional 80,155 shares during the period. Walleye Capital LLC raised its stake in shares of Evolent Health by 1,198.0% in the second quarter. Walleye Capital LLC now owns 647,761 shares of the technology company’s stock valued at $7,294,000 after buying an additional 597,858 shares during the period. Edgestream Partners L.P. purchased a new position in shares of Evolent Health during the 2nd quarter valued at $2,587,000. Finally, Ballentine Partners LLC bought a new position in shares of Evolent Health during the 2nd quarter worth $171,000.

Evolent Health Stock Down 2.6%

Evolent Health stock opened at $3.90 on Monday. The firm has a market capitalization of $434.69 million, a price-to-earnings ratio of -2.47 and a beta of 0.26. The firm’s fifty day moving average price is $4.59 and its two-hundred day moving average price is $7.73. Evolent Health has a 1-year low of $3.49 and a 1-year high of $12.98. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 1.25.

Evolent Health (NYSE:EVH) last posted its earnings results on Tuesday, June 4th. The technology company reported $0.21 EPS for the quarter. Evolent Health had a negative net margin of 6.24% and a positive return on equity of 1.79%. The company had revenue of $427.70 million during the quarter. On average, equities research analysts predict that Evolent Health will post 0.08 earnings per share for the current fiscal year.

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.